Clinical research studies

We currently support a number of clinical research studies, including:

  • AEGIS find out how effective and safe the study drug CSL112 is at reducing the risk of dying from heart related events, having another heart attack, or having a stroke.
  • AF Mapping – MFT sponsored observational study to understand why using cardiac ablation in treating atrial fibrillation (the most common heart rhythm disorder) is not always successful, as the reasons for this are currently unknown.
  • Cardio MEMS OUS – This Post Approval Study is evaluating the use of the CardioMEMS HF System in Heart Failure patients. It measures pulmonary artery pressure remotely from the patients home so medications can be adjusted accordingly.
  • Clinical Evaluation and Genetic Tests for Inherited Heart Conditions – We hope to determine which genes affect inherited heart conditions. Certain gene changes cause heart conditions. Others affect the severity of a condition. These are called modifiers. We are looking for these gene changes and modifiers to find out why some people are affected by a condition and why some are more severely affected than others.
  • DAPA MI Evaluating the Effect of Dapagliflozin on the Incidence of Heart
    Failure or Cardiovascular Death in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure.
  • DUAL – 1:1 Randomisation. To establish whether, in patients undergoing high-risk PCI, a strategy of percutaneous left ventricular unloading is superior to standard care in terms of patient outcomes, quality of life and cost-effectiveness.
  • EVAREST – The Use of Blood Biomarkers, Including Extracellular Vesicles, to Improve the Diagnostic Accuracy of Cardiac Assessment by Stress Echocardiogram.
  • EVOLVED – Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis.
  • FINEART-HF – Finerenone study drug to investigate its effectiveness and safety compared to placebo in patients with heart failure
  • FISH AND CHIPS – Looking at retrospective cardiovascular imaging in stable heart disease patients to see how we can improve patient care and societal cost
  • FLUTTER – comparing three standard of care procedures for catheter ablation:
    1. Fluoroscopically, using X-rays to guide the operator to visualise catheter position.                                            

    2. 3-dimensional mapping system which allows the catheters to be magnetically located and visualised on a monitor without X-rays.                   

    3. Using an ultra-high density mapping system which uses magnetic tracking as above, but allows higher resolution visualisation of the cardiac electrical system with potential for improving procedure success.

  • iMODERN – The purpose of this study is to investigate what is the best treatment for artery narrowings following a heart attack. There are currently several options, but it is unclear which one is best. This study will compare two treatment options: same day treatment of the narrowings, or MRI scan within 6 weeks to show whether the arteries are blocking blood flow to the heart muscle.
  • IRONMAN – Comparing the effectiveness of intravenous iron treatment vs standard care in patients with heart failure and iron deficiency.
  • LOCALIZE-CF – to collect data on the mapping system and ablation used when treating atrial fibrillation.
  • Medtronic Product Surveillance Registry: 1. Multi Point Pacing module and 2. Micra Acute Performance – Post-market product surveillance registry study to collect information about implanted leadless device and health.
  • OPTIMIZE – UK lead site where we will be collecting clinical evidence on valve performance and procedural outcomes associated with an optimized” TAVR care pathway and using the EvolutTM PRO and EvolutTM PRO+ devices.
  • PRAETORIAN – The aim of this study is to find out whether performing a defibrillation test after implantation of subcutaneous implantable cardioverter defibrillator (S-ICD) has an effect on the treatment of cardiac arrhythmias
  • PRE18FFIR – Study to use heart scanning technique to look at high risk plaques in heart arteries.
  • QUACS – finding out the quality of life of our patients before and after cardiac surgery.
  • RAPID N STEMI – Assessing two pathways for heart attacks. Group A: Immediate angiography/PCI. Group B: Standard angiography/PCI strategy <72 hours from admission.
  • REVIVED-BCIS2 – Comparing two options in treating heart failure patients.
  • STEP HFpEF – Assessing the effect of semaglutide once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction.
  • STEP HFpEF DM – Assessing the effect of semaglutide once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction and Type II diabetes.
  • SOLVE CRT – Cardiac Resynchrnoization Therapy (CRT) device using an ultrasound transmitter for non-responders and previously untreatable patients.
  • TRIAGE This evaluation aims to investigate the effort of implementing a new clinical pathway called ‘Triage HF+’. The pathway aims to identify patients whom may be experiencing worsening heart function based on data we receive from their cardiac device via a remote download that we receive in the Heart Centre.
  • UK TAVI – Comparison study looking at two ways of treating severe narrowing of aortic valve.

For more information about these studies and other research at the Manchester Heart Centre please contact Senior Clinical Research Nurse Thabitha Charles on  or 0161 276 3336.